|
1
|
Tham YC, Li X, Wong TY, Quigley HA, Aung T
and Cheng CY: Global prevalence of glaucoma and projections of
glaucoma burden through 2040: A systematic review and
meta-analysis. Ophthalmology. 121:2081–2090. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weinreb RN, Aung T and Medeiros FA: The
pathophysiology and treatment of glaucoma: A review. JAMA.
311:1901–1911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jia Y, Wei E, Wang X, Zhang X, Morrison
JC, Parikh M, Lombardi LH, Gattey DM, Armour RL, Edmunds B, et al:
Optical coherence tomography angiography of optic disc perfusion in
glaucoma. Ophthalmology. 121:1322–1332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gramlich OW, Ding QJ, Zhu W, Cook A,
Anderson MG and Kuehn MH: Adoptive transfer of immune cells from
glaucomatous mice provokes retinal ganglion cell loss in
recipients. Acta Neuropathol Commun. 3:562015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren
Z, Li X and Zhao M: Anti-VEGF treatment is the key strategy for
neovascular glaucoma management in the short term. BMC Ophthalmol.
16:1502016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu X, Yu X and Dai H: Intravitreal
injection of ranibizumab for treatment of age-related macular
degeneration: Effects on serum VEGF concentration. Curr Eye Res.
39:518–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berg K, Hadzalic E, Gjertsen I, Forsaa V,
Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR,
et al: Ranibizumab or bevacizumab for neovascular age-related
macular degeneration according to the lucentis compared to avastin
study treat-and-extend protocol: Two-year results. Ophthalmology.
123:51–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andreoli MT, Pinnolis M, Kieser T, Sun J
and Andreoli CM: Feasibility and efficacy of a mass switch from
ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of
neovascular age-related macular degeneration. Digit J Ophthalmol.
21:1–17. 2015.PubMed/NCBI
|
|
9
|
Kapetanakis VV, Chan MPY, Foster PJ, Cook
DG, Owen CG and Rudnicka AR: Global variations and time trends in
the prevalence of primary open angle glaucoma (POAG): A systematic
review and meta-analysis. Br J Ophthalmol. 100:86–93. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu L, Jia Y, Takusagawa HL, Pechauer AD,
Edmunds B, Lombardi L, Davis E, Morrison JC and Huang D: Optical
coherence tomography angiography of the peripapillary retina in
glaucoma. JAMA Ophthalmol. 133:1045–1052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kyari F, Wormald R, Murthy GV, Evans JR
and Gilbert CE: Nigeria National Blindness and Visual Impairment
Study Group: Ethnicity and deprivation are associated with
blindness among adults with primary glaucoma in nigeria: Results
from the nigeria national blindness and visual impairment survey. J
Glaucoma. 25:e861–e872. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gharahkhani P, Burdon KP, Fogarty R,
Sharma S, Hewitt AW, Martin S, Law MH, Cremin K, Bailey JNC, Loomis
SJ, et al: Wellcome Trust Case Control Consortium 2, NEIGHBORHOOD
consortium: Common variants near ABCA1, AFAP1 and GMDS confer risk
of primary open-angle glaucoma. Nat Genet. 46:1120–1125. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Narayanan R, Panchal B, Das T, Chhablani
J, Jalali S and Ali MH: MARVEL study group: A randomised,
double-masked, controlled study of the efficacy and safety of
intravitreal bevacizumab versus ranibizumab in the treatment of
macular oedema due to branch retinal vein occlusion: MARVEL Report
No. 1. Br J Ophthalmol. 99:954–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Türkcü FM, Cinar Y, Türkcü G, Sahin A,
Cingü AK, Yüksel H, Sahin M, Yıldırım A and Caça I: Topical and
subconjunctival ranibizumab (lucentis) for corneal
neovascularization in experimental rat model. Cutan Ocul Toxicol.
33:138–144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Froger NG, Forster V, Ivkovic I, Matonti
F, Sahel JA and Picaud SA: Ranibizumab (Lucentis®)
suppresses the autocrine VEGF-elicited survival of purified retinal
ganglion cells. Invest Ophthalmol Vis Sci. 55:2391. 2014.
|
|
16
|
Molokhia S, Burr RM, Flood M, Vallrath M,
Winter G and Ambati BK: Lens capsule biodegradable lipid implant
for sustained-release anti-VEGF therapy of neovascular AMD. Invest
Ophthalmol Vis Sci. 57:4004. 2016.
|
|
17
|
Korhonen T: Developing Medical Record for
Follow-Up of Wet Age-Related Macular DegenerationLeadership,
Innovation and Entrepreneurship as Driving Forces of the Global
Economy. Springer International Publishing; pp. 77–83. 2017,
View Article : Google Scholar
|
|
18
|
Niwa Y, Kakinoki M, Sawada T, Wang X and
Ohji M: Ranibizumab and aflibercept: Intraocular pharmacokinetics
and their effects on aqueous VEGF level in vitrectomized and
nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci.
56:6501–6505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson EC, Doser TA, Cepurna WO, Dyck JA,
Jia L, Guo Y, Lambert WS and Morrison JC: Cell proliferation and
interleukin-6-type cytokine signaling are implicated by gene
expression responses in early optic nerve head injury in rat
glaucoma. Invest Ophthalmol Vis Sci. 52:504–518. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fisher J, Mizrahi T, Schori H, Yoles E,
Levkovitch-Verbin H, Haggiag S, Revel M and Schwartz M: Increased
post-traumatic survival of neurons in IL-6-knockout mice on a
background of EAE susceptibility. J Neuroimmunol. 119:1–9. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bennett JL, Thomas S, Olson JL and Mandava
N: Treatment of nonarteritic anterior ischemic optic neuropathy
with intravitreal bevacizumab. J Neuroophthalmol. 27:238–240. 2007.
View Article : Google Scholar : PubMed/NCBI
|
